Eli Lilly's Obesity Pill Achieves Significant Weight Loss in Clinical Trials
TL;DR Summary
Eli Lilly's new oral obesity pill helped patients lose nearly 12% of their body weight in a late-stage trial, signaling a potential market entry in 2026 and offering a needle-free alternative to existing treatments, though side effects and discontinuation rates are considerations.
- Eli Lilly's obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for approval CNBC
- Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity Eli Lilly and Company
- Experimental GLP-1 pill helped people with obesity lose weight, Eli Lilly says CNN
- Lilly’s Obesity Pill Cut Body Weight by 11% in Key Study Bloomberg.com
- Pill Causes Major Weight Loss in Eli Lilly Trial’s Results The New York Times
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
6 min
vs 7 min read
Condensed
97%
1,243 → 42 words
Want the full story? Read the original article
Read on CNBC